3 days popular7 days popular1 month popular3 months popular

SMi’s 6th Annual Biomarkers Summit – Innovations In Stratified Medicine
, 16-17 January 2013, London

The drive towards is seeing pharma move from patient stratification as a ‘nice to have’, to an essential feature of product development. Exemplified by the success of Herceptin, promise to transform drug discovery, clinical development and in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity.

Drawing on advances in genomics, and clinical trial design, SMi’s sixth annual held on 16th &17th January 2013 London brings you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. Attending will enable you to:

  • Accelerate companion diagnostics development for therapeutic indications

  • Validate and deliver biomarkers for patient selection during
  • Implement sub-grouping in patient segmentation studies

  • Utilise revised FDA regulatory guidelines to aid product development

  • Optimise reimbursement strategies for diagnostics

  • Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit19.asp alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on [email protected]


SMi Group Ltd